Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Heerspink, Hiddo J. L.Sjöström, C. DavidJongs, NielsChertow, Glenn M.Kosiborod, M. N.Hou, Fan-FanMcMurray, John J.Rossing, PeterCorrea-Rotter, RicardoKurlyandskaya, RaisaStefánsson, Bergur V.Toto, Roberto D.Langkilde, Anna-MariaWheeler, David C.Nagy, Gergely György2025-01-092025-01-092021European Heart Journal. -42 : 13 (2021), p. 1216-1227. -Eur. Heart J. - 0195-668X0195-668Xhttps://hdl.handle.net/2437/384680Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM126504OrvostudományokKlinikai orvostudományokhttps://academic.oup.com/eurheartj/article/42/13/1216/6207268szerzőhttp://dx.doi.org/10.1093/eurheartj/ehab0942025-01-0900064625280000985103743786